Ketones, omega-3 fatty acids and the Yin-Yang balance in the brain: insights from infant development and Alzheimer's disease, and implications for human brain evolution

被引:6
|
作者
Cunnane, Stephen C. [1 ]
机构
[1] Univ Sherbrooke, Dept Med, Sherbrooke, PQ, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
brain; brain development; Alzheimer's disease; glucose; ketones; beta-hydroxybutyrate; aging; omega-3 fatty acids; alpha-linolenic acid; eicosapentaenoic acid; docosahexaneoic acid;
D O I
10.1051/ocl/2018020
中图分类号
S3 [农学(农艺学)];
学科分类号
0901 ;
摘要
Optimal brain performance is intimately linked to the brain's Yin and the Yang - the balance between its structure and its energy metabolism. This relationship is clearly exemplified in infant brain development and in Alzheimer's disease, and probably also applies to human brain evolution. In these examples, redundant pathways help achieve this important balance. For instance, the key structural lipid for the brain, docosahexaenoic acid (DHA), is supplied to the infant brain from at last three overlapping sources: (i) milk; (ii) infant's own fat stores and (iii) by some endogenous synthesis from alpha-linolenic acid (ALA) or eicosapentaenoic acid (EPA). On the energy side, glucose is normally the brain's main fuel but under conditions of prolonged starvation, it can be almost totally replaced by the ketone bodies, acetoacetate and beta-hydroxybutyrate. When ketones are present in the blood they spare glucose uptake by the brain because they are actually the brain's preferred fuel and are essential for normal infant brain development. The redundant sources of ketones are long chain fatty acids (including the relatively ketogenic ALA) in infant stores, and medium chain triglycerides (MCT) in milk. Besides infancy, nowhere is the strain on the brain's balance between yin and yang more apparent than in Alzheimer's disease (AD). One of the reasons why attempts to treat AD have largely failed could well be because chronically inadequate glucose supply to some areas of the brain on the order of 10% is present in people at risk of AD long before cognitive decline begins. However, brain ketone uptake is still normal even in moderately advanced AD. Hence, treatments that ignore the brain energy (glucose) deficit in AD would be predicted to fail, but treatments that attempt to rescue brain fuel availability via ketones would be predicted to have a better chance of succeeding. By analogy to ketones sparing glucose for brain energy metabolism, perhaps ALA or EPA entering the brain can help spare (conserve) DHA for its structural role. If so, it would not necessarily be futile to transport ALA and EPA into the brain just to beta-oxidize the majority afterwards; DHA sparing as well as ketone production could be important beneficiaries.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Insights from a proteomic atlas of human Alzheimer's disease brain tissue
    Kavanagh, Tomas
    Drummond, Eleanor
    NEURAL REGENERATION RESEARCH, 2025, 20 (03) : 799 - 800
  • [42] Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer’s disease
    Amy H. R. Wood
    Helen F. Chappell
    Michael A. Zulyniak
    European Journal of Nutrition, 2022, 61 : 589 - 604
  • [43] Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer's Disease: The OmegAD Study
    Freund-Levi, Yvonne
    Hjorth, Erik
    Lindberg, Catharina
    Cederholm, Tommy
    Faxen-Irving, Gerd
    Vedin, Inger
    Palmblad, Jan
    Wahlund, Lars-Olof
    Schultzberg, Marianne
    Basun, Hans
    Jonhagen, Maria Eriksdotter
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 27 (05) : 481 - 490
  • [44] Effects of Supplementation with Omega-3 Fatty Acids on Oxidative Stress and Inflammation in Patients with Alzheimer's Disease: The OmegAD Study
    Freund-Levi, Yvonne
    Vedin, Inger
    Hjorth, Erik
    Basun, Hans
    Irving, Gerd Faxen
    Schultzberg, Marianne
    Eriksdotter, Maria
    Palmblad, Jan
    Vessby, Bengt
    Wahlund, Lars-Olof
    Cederholm, Tommy
    Basu, Samar
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 42 (03) : 823 - 831
  • [45] Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined
    Nolan, John M.
    Mulcahy, Riona
    Power, Rebecca
    Moran, Rachel
    Howard, Alan N.
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 (02) : 367 - 378
  • [46] Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer's disease
    Wood, Amy H. R.
    Chappell, Helen F.
    Zulyniak, Michael A.
    EUROPEAN JOURNAL OF NUTRITION, 2022, 61 (02) : 589 - 604
  • [47] Omega-3 blood biomarkers relate to brain glucose uptake in individuals at risk of Alzheimer's disease dementia
    Lazaro, Iolanda
    Grau-Rivera, Oriol
    Suarez-Calvet, Marc
    Fauria, Karine
    Minguillon, Carolina
    Shekari, Mahnaz
    Falcon, Carles
    Garcia-Prat, Marina
    Huguet, Jordi
    Molinuevo, Jose Luis
    Gispert, Juan-Domingo
    Sala-Vila, Aleix
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2024, 16 (03)
  • [48] Omega-3 Polyunsaturated Fatty Acids and Blood-Brain Barrier Integrity in Major Depressive Disorder: Restoring Balance for Neuroinflammation and Neuroprotection
    Zailani, Halliru
    Wang, Wen-Lung
    Satyanarayanan, Senthil Kumaran
    Chiu, Wei-Che
    Liu, Wen-Chun
    Sung, Yi-Shan
    Chang, Jane Pei-Chen
    Su, Kuan-Pin
    YALE JOURNAL OF BIOLOGY AND MEDICINE, 2024, 97 (03): : 349 - 363
  • [49] Evolution of the Human Brain: the key roles of DHA (omega-3 fatty acid) and Delta 6-desaturase gene
    Majou, Didier
    OCL-OILSEEDS AND FATS CROPS AND LIPIDS, 2018, 25 (04)
  • [50] Editorial: Is it time to separate EPA from DHA when using omega-3 fatty acids to protect heart and brain?
    Deckelbaum, Richard J.
    Calder, Philip C.
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2020, 23 (02): : 65 - 67